John Galbincea

PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

Hallmarks of Cancer: The Next Generation

Establishing the Diagnosis of Lung Cancer

Analysis of the genome to personalize therapy for melanoma

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

Macrophages in immunoregulation and therapeutics

EMT Transition States during Tumor Progression and Metastasis

Cancer-associated cachexia

Molecular characterization ofde novoPhiladelphia chromosome-positive acute myeloid leukemia

Targeting RAS–ERK signalling in cancer: promises and challenges

Liquid biopsies come of age: towards implementation of circulating tumour DNA

A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models

Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML

EGFR and KRAS mutations in lung carcinoma

The PI3K Pathway in Human Disease

Maftools: efficient and comprehensive analysis of somatic variants in cancer

Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

Which melanoma patient carries a BRAF-mutation? A comparison of predictive models

Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma

Acute Myeloid Leukemia With IDH1 or IDH2 Mutation

Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma

Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type

Application of COLD-PCR for improved detection of KRAS mutations in clinical samples

Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays

The Search Continues

Cutaneous carcinosarcoma: further insights into its mutational landscape through massive parallel genome sequencing